4-Amino-3-Chlorophenol CAS 17609-80-2 Lenvatinib Mesylate Intermediate Purity > 99.0% (HPLC)
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates Nrog Siab Purity
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Tom ntej: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Tom ntej: Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Tom ntej: Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Tshuaj npe | 4-Amino-3-Chlorophenol |
Synonyms | 3-Chloro-4-Aminophenol;Lenvaint-G |
CAS Nr | 17609-80-2 |
CAT Number | RF-PI 1968 |
Tshuag xwm txheej | Nyob rau hauv Tshuag, ntau lawm Scale mus txog Tons |
Molecular Formula | C6H6ClNO |
Molecular Luj | 143.57 Nws |
Qhov ntom | 1.406 ± 0.060g / cm3 |
Hom | Ruifu Tshuaj |
Yam khoom | Specifications |
Qhov tshwm sim | Brown Solid Powder |
1 H NMR Spectrum | Raws li tus qauv |
Identification-HPLC | Lub sijhawm khaws cia zoo ib yam li tus qauv |
Purity / Analysis Method | > 99.0% (HPLC) |
Melting Point | 138.0 ~ 141.0 ℃ |
Poob rau ziab | <1.00% |
Residue ntawm Ignition | <0.30% |
Tag nrho cov impurities | <1.00% |
Test Standard | Enterprise Standard |
Kev siv | Intermediate ntawm Lenvatinib Mesylate (CAS: 857890-39-2) |
Pob: Lub raj mis, Aluminium ntawv ci hnab, 25kg / Cardboard Nruas, los yog raws li tus neeg yuav tsum tau muaj
Cia txias:Khaws rau hauv cov thawv ntim khoom ntawm qhov chaw txias thiab qhuav;Tiv thaiv los ntawm lub teeb thiab noo noo
4-Amino-3-Chlorophenol (CAS: 17609-80-2) yog ib qho tseem ceeb kws tshuaj nruab nrab, uas yog dav siv nyob rau hauv kev tsim thiab synthesis ntawm anti-tumor, kab mob plawv, neurological kab mob tshuaj.4-Amino-3-Chlorophenol yog ib qho tseem ceeb nruab nrab ntawm kev npaj ntawm Lenvatinib Mesylate (CAS: 857890-39-2).Tsim los ntawm Eisai Inc., lenvatinib mesylate yog vascular endothelial growth factor receptor (VEGF) inhibitor uas muaj kev ua haujlwm tiv thaiv VEGF subtypes 1, 2, thiab 3 thiab tau pom zoo los ntawm FDA hauv 2015 rau kev kho mob qog noj ntshav sib txawv hauv zos. rov tshwm sim, metastatic, lossis kev loj hlob thiab tsis teb rau kev kho mob radioactive iodine.Nyob rau lub Tsib Hlis 2016, FDA tau pom zoo cov tshuaj raws li kev kho mob ua ke nrog everolimus rau kev kho mob ntawm lub raum cell carcinoma.Vim tias VEGF (thiab fibroblast kev loj hlob zoo tshaj plaws receptors, hu ua FGFRs) tau xav tias ua lub luag haujlwm hauv cov hlab plawv cov hlab ntsha, VEGF2R thiab FGFR inhibition tau xav tias yog cov txheej txheem tom qab thawj cov kev mob tshwm sim ntawm lenvatinib mesylate, uas yog kub siab.